Gerresheimer increased revenues by 4.2%
Gerresheimer increased revenues in the second quarter of financial year 2013 (financial year from December 1 to November 30) by 4.2% to 327.1 million euros. The revenue growth mainly reflects strong business in the Plastic Systems Division with pharmaceutical primary packaging, insulin pens and inhalers.
Triveni, an Indian company specializing in pharmaceutical plastic packaging acquired in December 2012, likewise contributed to the increase in revenues. The Moulded Glass Division generated healthy growth rates notably with the sale of cosmetic glass packaging.
"Our strategy is geared to sustained, profitable growth. We continue to be successful in implementing that strategy. In the second quarter, we saw notable growth particularly in our medical systems for drug delivery and in pharmaceutical plastic packaging. Our latest acquisitions in India are also developing very well," said Uwe Röhrhoff, CEO of Gerresheimer AG.
Gerresheimer recorded adjusted EBITDA of EUR 59.8m in the second quarter of 2013, an increase of 0.5% on the prior-year quarter. The adjusted EBITDA margin was 18.3%, below the 19.0% margin in the comparative period.
The main causes of the decreased margin comprised the anticipated high cost of improving the production of prefillable syringes at a German plant and quality problems in the manufacture of glass ampoules identified at a Mexican plant during the second quarter.
Adjusted net income for the second quarter came to EUR 21.5m, 0.9% more than in the prior-year quarter (EUR 21.3m). Adjusted earnings per share were exactly on a par with the prior-year quarter, at EUR 0.63. Gerresheimer’s capital expenditure in the second quarter of 2013 was EUR 33.4m, EUR 2.0m more than a year earlier.
For financial year 2013, Gerresheimer continues to expect revenue growth of 5% to 6% at constant exchange rates. ■